Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Europe and Israel or involving organisations from these countries.

Total search results: 6297 | Ordered by Date (descending)
1 2 3 ... 61 62 63  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cellares–SEVERAL: investment, 202105 financing round Series B $82m led by Decheng Capital + Eclipse Ventures 2021-05-05
Cellares–Skyviews Life Science: investment, 202105 financing round Series B totalling $82m incl new + co-investor Skyviews Life Science 2021-05-05
Cytoki Pharma–+ND Capital: investment, 202105 financing round Series A totalling $45m incl co-investor +ND Captial 2021-05-05
Cytoki Pharma–BPCE: investment, 202105 financing round Series A totalling $45m incl co-investor Seventure Partners 2021-05-05
Cytoki Pharma–Lundbeck: investment, 202105 financing round Series A totalling $45m incl existing + lead investor Lundbeckfonden Emerge 2021-05-05
Cytoki Pharma–SEVERAL: investment, 202105 financing round Series A $45m led by existing investor Lundbeckfonden Emerge 2021-05-05
Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital 2021-05-05
Athenex–Cooley: legal services, 202105 supply service Cooley (UK) acted as sole advisor to Athenex with regard to acquisition of Kuur Therapeutics 2021-05-04
Kuur Therapeutics–Athenex: investment, 202105 acquisition $70m upfront (mainly in shares) + $115m milestones by Athenex 2021-05-04
Kuur Therapeutics–HMB Legal Counsel: legal services, 202105 supply service HMB Legal legal advisor to Kuur with regard to acquisition by Athenex 2021-05-04
Kuur Therapeutics–SVB: financial services, 202105 supply service SVB Lerrink financial adivsor to Kuur with regard to acquisition by Athenex 2021-05-04
Oxford Nanopore–SEVERAL: investment, 202105 financing round £195m from new + existing investors 2021-05-04
Aquila Biolabs–Scientific Industries: investment, 202104 acquisition of Aquila Biolabs GmbH by Scientific Bioprocessing Inc 2021-04-30
Adcendo–Gilde Investment: investment, 202104 financing round Series A totalling €51m incl co-investor Gilde Healthcare 2021-04-29
Adcendo–Novo Group: investment, 202104 financing round Series A totalling €51m incl co-lead investor Novo Seeds 2021-04-29
Adcendo–Odlander Fredrikson: investment, 202104 financing round Series A totalling €51m incl co-investor RA HealthCap 2021-04-29
Adcendo–Optimum Strategic Communications: public relations, 202104 service existent by Optimum 2021-04-29
Adcendo–RA Capital: investment, 202104 financing round Series A totalling €51m incl co-investor RA Capital Management 2021-04-29
Adcendo–SEVERAL: investment, 202104 financing round Series A €51m co-led by Novo Seeds + Ysios Capital 2021-04-29
Adcendo–Ysios Capital: investment, 202104 financing round Series A totalling €51m incl co-lead investor Ysios Capital 2021-04-29
Valneva–SEVERAL: investment, 202104– European private placement ANNOUNCED 2021-04-29
Valneva–SEVERAL: investment, 202104– US IPO of ADSs at Nasdaq Global Market ANNOUNCED 2021-04-29
Agendia–Inivata: cancer test, 202104– co-excl distribution rights €na for RaDaR liquid biopsy assay for breast cancer in North America + Europe 2021-04-28
Kaia Health–3VC: investment, 202104 financing round Series C totalling $75m incl existing + co-investor 3VC 2021-04-28
Kaia Health–A Round Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor A Round Capital 2021-04-28
Kaia Health–Balderton Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Balderton Capital 2021-04-28
Kaia Health–Eurazeo: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Eurazeo 2021-04-28
Kaia Health–Heartcore Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Heartcore Capital 2021-04-28
Kaia Health–Hot Cherry PR: public relations, 202104 service existent by Hot Cherry PR 2021-04-28
Kaia Health–OTHER: investment, 202104 financing round Series C totalling $75m incl undisclosed growth equity fund as lead investor 2021-04-28
Kaia Health–SEVERAL: investment, 202104 financing round Series C $75m led by undisclosed growth equity fund 2021-04-28
Kaia Health–Symphony Ventures: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Symphony Ventures 2021-04-28
Kaia Health–UnitedHealth: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Optum Ventures 2021-04-28
Exciva–Andera Partners: investment, 202104 existent investment of Andera Partners 2021-04-27
Exscientia–BlackRock: investment, 202104 financing round Series D totalling $225m incl existing + co-investor BlackRock 2021-04-27
Exscientia–BMS: investment, 202104 financing round Series D totalling $225m incl existing + co-investor BMS 2021-04-27
Exscientia–Casdin Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Casdin Capital 2021-04-27
Exscientia–Farallon Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Farallon Capital 2021-04-27
Exscientia–GT Healthcare Capital Partners: investment, 202104 financing round Series D totalling $225m incl co-investor GT Healthcare 2021-04-27
Exscientia–Hongkou: investment, 202104 financing round Series D totalling $225m incl co-investor Hongkou 2021-04-27
Exscientia–Laurion Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Laurion Capital 2021-04-27
Exscientia–Marshall Wace: investment, 202104 financing round Series D totalling $225m incl co-investor Marshall Wace 2021-04-27
Exscientia–Nan Fung: investment, 202104 financing round Series D totalling $225m incl co-investor Pivotal bioVenture Partners 2021-04-27
Exscientia–Novo Group: investment, 202104 financing round Series D totalling $225m incl existing + co-investor Novo Holdings 2021-04-27
Exscientia–SEVERAL: investment, 202104 financing round Series D $225m led by SoftBank Vision Fund 2 2021-04-27
Exscientia–SoftBank: investment, 202104 financing round Series D totalling $225m incl lead investor SoftBank Vision Fund 2 2021-04-27
Exscientia–SoftBank: investment, 202104– equity commitment up to $300m by SoftBank than can be drawn at Exscientia’s discretion 2021-04-27
Exscientia–United Arab Emirates (govt): investment, 202104 financing round Series D totalling $225m incl co-investor Mubadala Investment Company 2021-04-27
Mablink Bioscience–SEVERAL: investment, 202104 seed financing round €4m led by Elaia Partners 2021-04-27
PreComb Therapeutics–FiveT Capital: investment, 202104 seed financing round totalling CHF2.2m incl co-lead investor FiveT Capital 2021-04-26
PreComb Therapeutics–High-Tech Gründerfonds: investment, 202104 seed financing round totalling CHF2.2m incl co-lead investor HTGF 2021-04-26
PreComb Therapeutics–Kinled: investment, 202104 seed financing round totalling CHF2.2m incl co-lead investor Kinled Austria 2021-04-26
PreComb Therapeutics–SEVERAL: investment, 202104 seed financing round CHF2.2m led by Kinled Austria + HTGF + FiveT Capital 2021-04-26
Molecular Partners–SEVERAL: investment, 202104– US IPO at Nasdaq FILED 2021-04-23
Anavo Therapeutics–ABP (NL): investment, 202104 seed financing round totalling €20m incl co-lead investor Inkef Capital 2021-04-22
Anavo Therapeutics–Bioqube Ventures: investment, 202104 seed financing round totalling €20m incl co-investor Bioqube Ventures 2021-04-22
Anavo Therapeutics–MacDougall Advisors: public relations, 202104 service existent by MacDougall 2021-04-22
Anavo Therapeutics–Merck (DE): investment, 202104 seed financing round totalling €20m incl co-lead investor M Ventures 2021-04-22
Anavo Therapeutics–Otsuka: investment, 202104 seed financing round totalling €20m incl co-investor Taiho Ventures 2021-04-22
Anavo Therapeutics–SEVERAL: investment, 202104 seed financing round €20m led by M Ventures + Inkef Capital 2021-04-22
Forbion–SEVERAL: investment, 202104 additional €175m + final closing at hard cap of €360m of Forbion Growth Opportunities Fund I 2021-04-20
Forbion–Wealth Management Partners: investment, 202104 final closing at €360m of Forbion Growth Opportunities Fund I incl investor WMP 2021-04-20
Gamut Therapeutics–SparingVision: investment, 202104– acquisition €na mainly in shares ANNOUNCED 2021-04-20
Mestag Therapeutics–JnJ: investment, 202104 seed financing round totalling $11m incl Johnson & Johnson Innovation JJDC Inc 2021-04-20
Mestag Therapeutics–JW Communications: public relations, 202104 service existent by JW Communications 2021-04-20
Mestag Therapeutics–SEVERAL: investment, 202104 seed financing round $11m with SV Health Investors + JJDC 2021-04-20
Mestag Therapeutics–SV Health Investors: investment, 202104 seed financing round totalling $11m incl SV Health Investors 2021-04-20
Rinri Therapeutics–BioCity (GB): investment, 202104 financing round totalling £10m incl existing investor BioCity 2021-04-20
Rinri Therapeutics–Boehringer: investment, 202104 financing round totalling £10m incl existing investor BIVF 2021-04-20
Rinri Therapeutics–SEVERAL: investment, 202104 financing round £10m from existing investors + incl convertible loan from UK Future Fund 2021-04-20
Rinri Therapeutics–UCB: investment, 202104 financing round totalling £10m incl existing investor UCB Ventures 2021-04-20
Rinri Therapeutics–United Kingdom (govt): credit, 202104 financing totalling £10m incl convertible loan from UK Future Fund 2021-04-20
Sense Biodetection–Cambridge Innovation Capital: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor CIC 2021-04-20
Sense Biodetection–Earlybird: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor Earlybird Health 2021-04-20
Sense Biodetection–Koch Industries: investment, 202104 financing round Series B totalling $50m incl new + lead investor Koch Disruptive Technologies 2021-04-20
Sense Biodetection–Mercia: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor Mercia Asset Management 2021-04-20
Sense Biodetection–PERSON: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor Jonathan Milner 2021-04-20
Sense Biodetection–SEVERAL: investment, 202104 financing round Series B $50m led by Koch Disruptive Technologies 2021-04-20
Synendos Therapeutics–Ysios Capital: investment, 202104 investment by new investor Ysios Capital extends financing round Series A to CHF24m 2021-04-20
Lumicks–Farallon Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Farallon Capital 2021-04-16
Lumicks–Gilde Investment: investment, 202104 financing round Series D totalling $93m preferred shares incl existing + co investor Gilde HC 2021-04-16
Lumicks–Irving Investors: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Irving Investors 2021-04-16
Lumicks–Lauxera Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Lauxera Capital 2021-04-16
Lumicks–Parian Global Management: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Parian Global Mgt 2021-04-16
Lumicks–Pura Vida Investments: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Pura Vida 2021-04-16
Lumicks–SEVERAL: investment, 202104 financing round Series D $93m preferred shares led by Farallon Capital + Lauxera Capital 2021-04-16
Lumicks–Softbank: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Softbank Vision 2 2021-04-16
Lumicks–T Rowe Price: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor funds managed by T Rowe Price 2021-04-16
Alchemab–RA Capital: investment, 202104 financing round Series B totalling £60m incl lead investor RA Capital Management 2021-04-15
Alchemab–SEVERAL: investment, 202104 financing round Series B £60m led by RA Capital Management 2021-04-15
Alligator Bioscience–MacroGenics: antibody cancer drug, 202104– collab research using Neo-X-Prime plus DART+TRIDENT technologies against two targets 2021-04-15
ATMPS–Oribiotech: CAGT manufacturing technology, 202104– collab ww for integrated digital patform for CAGT developers using Hataali platform 2021-04-14
BioVersys–EU (govt): credit, 202104– venture debt loan up to €20m in three tranches from EIB 2021-04-14
Camtech Diagnostics–Congenica: bioinformatics, 202104– distribution of Congenica’s platform in SG+MY+JP+KR 2021-04-13
Quercis Pharma–Rx Communications: public relations, 202104 service existent IR by Rx Communications Group 2021-04-13
Repertoire Immune Medicines–SEVERAL: investment, 202104 financing round Series B $189m incl Flagship Pioneering + Softbank + PSP Investments et al 2021-04-13
Siemens–Biognosys: MS-based biomarker discovery, 202104– strategic agreem marker discovery using HRM-MS for Dx assay development with S Healthineers 2021-04-13
Mestex–Grünenthal: investment, 202104 acquisition 100% of Mestex AG by Grünenthal 2021-04-12
Luminex–DiaSorin: investment, 202104– acquisition $1.8b in cash for $37/share by DiaSorin ANNOUNCED 2021-04-11
Tidal Therapeutics–Sanofi: investment, 202104 acquisition $160m upfront + $310m milestones by Sanofi 2021-04-09
1 2 3 ... 61 62 63  next pagenext page



Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px

» top